Vitiligo

STRATA Skin Sciences to Participate at Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Retrieved on: 
Friday, December 2, 2022
Cantor, Fontainebleau Miami Beach, Screening Partnership Program, Ophthalmology, Conference, STRATA, Psoriasis, Strata Skin Sciences, Acne, Marketing, Maintenance, Partnership, Vitiligo, Medical imaging

Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Key Points: 
  • Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
    Panel: Aesthetically Pleasing & Medically Necessary: Leading Aesthetic & Medical Dermatology Devices
    Please contact your Cantor representative for more information.
  • STRATA Skin Sciencesis a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne.
  • Its products include the XTRAC and Pharos excimer lasers, VTRAC lamp systems, and now the TheraClearX Acne Therapy System.
  • STRATA is proud to offer these exciting technologies in theU.S.through its unique Partnership Program.

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Retrieved on: 
Tuesday, November 29, 2022
US Foods, Laboratory, Australian Securities Exchange, Chemistry, Vitiligo, Inflammatory bowel disease, Anxiety, Patient, Doctor of Philosophy, Incidence, Environment, Addiction, Immune system, Skin, Pain, Pigment, ASX, OSA, Rheumatoid arthritis, FDA, Concussion, Food, Genomics, Sleep apnea, Traumatic brain injury, TBI, Cannabinoid, Disease, Patent, American depositary receipt, CDMO, Atopic dermatitis, Safety, Dermatitis, Acquisition, Contract research organization, Pharmacology, COPD, CBG, Asthma, U.S. FDA, Psoriasis, Bronchitis, Pharmaceutical industry, Vaccine, Cannabigerol, Cannabidiol, Eurofins Scientific, MD

A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.

Key Points: 
  • A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.
  • In the study, ReneCann reduced disease scores in patients with each of the target skin diseases.
  • ReneCann also has the potential to be assessed for efficacy in other diseases where topical application may provide a benefit over conventional oral dosed cannabinoid formulations.
  • Incannex is investigating the use of Eurofins to develop and manufacture additional drug candidates acquired via the acquisition of APIRx Pharmaceuticals.

Meet Jim Corbett - Chief Executive Officer, AVITA Medical, Inc.

Retrieved on: 
Friday, November 18, 2022
Boston Scientific, Skin, Avita Medical, Burn, PMDA, Food, Health care, Jim Corbett, USE, Safety, Adam Scime, Regenerative medicine, Autotransplantation, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, EV3, PMA, GM, Contraindication, Vitiligo, Burns, FDA, Management, Telescopic sight, Motor vehicle, Pharmaceutical industry

Valencia, California--(Newsfile Corp. - November 17, 2022) - On September 28, 2022, AVITA Medical, Inc. appointed Jim Corbett as Chief Executive Officer, effective immediately.

Key Points: 
  • Valencia, California--(Newsfile Corp. - November 17, 2022) - On September 28, 2022, AVITA Medical, Inc. appointed Jim Corbett as Chief Executive Officer, effective immediately.
  • Throughout Jim's career, he has served as CEO of 3 publicly traded companies: MTIX (Microtherapeutics), ev3, and Alphatec Spine.
  • AVITA Medical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration.
  • AVITA Medical's first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018.

AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
Skin, Avita Medical, Burn, Piper Sandler Companies, PMDA, Food, Conference, Health care, AVH, USE, Safety, Regenerative medicine, ASX, Autotransplantation, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, Webcast, Contraindication, Vitiligo, Burns, FDA, Medical device, Pharmaceutical industry

A live audio webcast of the presentation will be available on the Events page of the companys website at ir.avitamedical.com .

Key Points: 
  • A live audio webcast of the presentation will be available on the Events page of the companys website at ir.avitamedical.com .
  • Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
    AVITAMedical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration.
  • AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018.
  • The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

AVITA Medical® to Host Investor Webinar Briefing

Retrieved on: 
Thursday, November 17, 2022
CFO, Skin, Avita Medical, Burn, PMDA, Food, Health care, AVH, USE, Safety, Regenerative medicine, ASX, Autotransplantation, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, AEDT, Contraindication, Vitiligo, Burns, FDA, PST, Medical device, Pharmaceutical industry

To register for the presentation, please follow this Zoom link: https://us02web.zoom.us/webinar/register/5016686405270/WN_JRqy-JXkQP2gCa...

Key Points: 
  • To register for the presentation, please follow this Zoom link: https://us02web.zoom.us/webinar/register/5016686405270/WN_JRqy-JXkQP2gCa...
    Participants are invited to submit questions via the registration page or during the webinar via the chat function.
  • A replay will be available on the AVITA Medical website, ir.avitamedical.com , following the presentation.
  • AVITAMedical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration.
  • AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018.

VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Retrieved on: 
Thursday, November 17, 2022
COVID-19, Regulation, Patient, Skin, Pharmacokinetics, Prevalence, Disclosure, Cell, Safety, Knowledge, Therapy, Physician, Contagious disease, Biomarker, Vitiligo, Patent, Research, Intellectual property, Failure, Regulation Fair Disclosure, Melanocyte, WNT, Clinical trial, Photography, BET, FDA, Pharmaceutical industry

The clinical trial is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers as well as provide early clinical proof-of-concept data in vitiligo patients.

Key Points: 
  • The clinical trial is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers as well as provide early clinical proof-of-concept data in vitiligo patients.
  • We look forward to topline data for both the Phase 1a and Phase 1b portions of the study, expected in the first half of 2023.
  • In the Phase 1b portion, up to 30 patients with a clinical diagnosis of non-segmental vitiligo will receive VYN201 once daily in up to three dose cohorts.
  • The Company expects to extend the treatment period for up to an additional 12 weeks, subject to ongoing nonclinical safety assessments.

Key patent issued on Eligo's gene editing breakthroughs applied to skin disorders

Retrieved on: 
Tuesday, November 15, 2022
GlaxoSmithKline, Acne, CRISPR, Gene editing, Maintenance, Hair follicle, European Commission, Skin, B cell, Gene, Efficiency, Genetic engineering, Khosla Ventures, US, MIT, Bacteria, Patent, Program, Technology, Patient, Rockefeller University, World Economic Forum, Inflammation, Vaccination, Skin cancer, Vitiligo, Immune system, Royal commission, Science, C, United States patent law, Hair, Antibiotics, Pharmaceutical industry, Vaccine, Cutibacterium

This pioneering work also provides unique opportunities to leverage the skin's immune system for oncological, vaccination or desensitization applications.

Key Points: 
  • This pioneering work also provides unique opportunities to leverage the skin's immune system for oncological, vaccination or desensitization applications.
  • No genetic toolbox was yet in existence for this notoriously difficult-to-engineer bacterial species before Eligo achieved these long-awaited genetic engineering breakthroughs.
  • C. acnes is a key and ubiquitous species of the skin microbiome that provides many health benefits for the host, such as maintenance of skin barrier and protection against pathogens.
  • Patent family WO2022096596 fully supports Eligo's acne program and many other serious skin disorders such as skin cancer, alopecia and vitiligo, as well as a tool for potential vaccination and desensitization.

AVITA Medical Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Forward-looking statement, Marketing, Burns, Health care, Adult, Autotransplantation, Calendar, U.S. Securities and Exchange Commission, Food, Ministry, Research, Telephone, Burn, Contraindication, Holocene, Regulation of tobacco by the U.S. Food and Drug Administration, BARDA, AVH, Failure, NASDAQ, Avita Medical, PMDA, Safety, EBITDA, MHLW, Regenerative medicine, Company, Adjustment, PMA, Clinical trial, Vitiligo, ASX, GAAP, Skin, USE, Patient, Growth, Security (finance), Industry, FDA, Medical device, Video game, Pharmaceutical industry, Risk management, Welfare, Health

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter ended September 30, 2022.
  • The Company will host a conference call to discuss the third quarter financial results after NASDAQ market close on Thursday, November 10, 2022, at 1:30 p.m. Pacific Time (being Friday, November 11, 2022, at 8:30 a.m. Australian Eastern Daylight Time).
  • AVITA Medical has provided in this release certain financial information that has not been prepared in accordance with GAAP.
  • However, the non-GAAP financial measures that AVITA Medical uses may differ from measures that other companies may use.

AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Federal, Office of the Assistant Secretary for Preparedness and Response, Burns, Health care, Adult, Autotransplantation, Biomedical Advanced Research and Development Authority, Food, Burn, Contraindication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AVH, NASDAQ, Avita Medical, Control, PMDA, Achievement, Safety, Assistant, Regenerative medicine, PMA, Clinical trial, ASX, USE, Vitiligo, Skin, Patient, Contract research organization, FDA, Medical imaging, Pharmaceutical industry

Both co-primary endpoints have been met:

Key Points: 
  • Both co-primary endpoints have been met:
    These results reinforce the potential for RECELL to become a new standard of care for soft tissue repair, said Jim Corbett, AVITA Medical Chief Executive Officer.
  • We look forward to sharing the soft tissue repair outcomes with the FDA via our PMA submission expected in December 2022.
  • AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018.
  • The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
Janus, GLOBE, AstraZeneca, JAMA, Investigational New Drug, Intellectual property, IND, Journal of the European Academy of Dermatology and Venereology, Director, Skin, Shanda, FDA, Nasdaq, Webcast, New Drug Application, PDE4, Completeness, PAP, U.S. Securities and Exchange Commission, Board, G&A, R, Atopic dermatitis, SEC, American Medical Association, Board of directors, Company, Dermatitis, Clinical trial, Journal, Research, Vitiligo, Psoriasis, Patient, Physician, Growth, Awareness, Pharmacy, Scalp, Acquisition, NDA, JAK1, Ageing, Congress, Fine chemical, Pharmaceutical industry, Cosmetics, Medical device, Venereology, Facebook, Dermatology

Effective November 2022, ZORYVE is now covered by one of the top pharmacy benefit managers and a large national health plan.

Key Points: 
  • Effective November 2022, ZORYVE is now covered by one of the top pharmacy benefit managers and a large national health plan.
  • In September 2022, Arcutis announced positive topline results from the ARRECTOR pivotal Phase 3 trial for the treatment of scalp and body psoriasis.
  • Ms. Krishnamohan brings a depth of business, financial and investment experience, including deep knowledge of Arcutis' business having previously worked on the Company's initial public offering.
  • Arcutis management will host a conference call and webcast today at 5:00pm ET to discuss the financial results for the quarter and provide a business update.